- Details
- In a conversation between Alicia Morgans and Professor Laura-Maria Krabbe, they discuss the treatment of non-metastatic, castration-resistant prostate cancer (M0CRPC). They highlight the importance of identifying high-risk patients based on PSA doubling time and the need for treatment intensification in this population. They also mention the role of PSMA PET scans in determining the extent of dise...
|
- Details
- Alicia Morgans interviews Nicholas James about the RADICALS trial, a complex study aiming to determine the optimal timing for radiotherapy after surgery and the amount of hormone therapy needed. The first question's data showed that waiting was safe and adjuvant therapy unnecessary. The second question, presented at ESMO, involved pragmatic randomization between zero, six, and 24 months of ADT, re...
|
- Details
- Alicia Morgans interviews Karim Fizazi to discuss his presentation on the CYPIDES Phase I-II trial. The trial focuses on ODM-208, a CYP11 inhibitor developed with Orion, aimed at treating men with advanced prostate cancer who have exhausted conventional therapies and exhibit androgen receptor mutations. Dr. Fizazi explains that the compound targets the precursor enzymes for various steroids, there...
|
- Details
- Jonathan Rosenberg discusses the promising results from Cohort K, a part of a multi-cohort phase 1B/2 study examining enfortumab in combination with other agents, notably pembrolizumab. The primary endpoint, objective response rate, indicates a 64.5% response with the combination treatment. This rate is significant compared to a 45% response observed with enfortumab monotherapy. Dr. Rosenberg also...
|
- Details
- Noel Clarke joins Alicia Morgans in discussing an updated analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). PROpel was born out of positive findings from the PROfound trial and a Phase II study, known as Study 08, which looked at whether...
|
- Details
- Alicia Morgans speaks with Neal Shore, focusing on the PROpel study which evaluates the efficacy of Olaparib and Abiraterone versus Abiraterone alone in treating first-line metastatic castration-resistant prostate cancer. Dr. Shore expresses excitement over the positive findings, particularly the benefits seen across all patient populations, not just those with HRR mutations. The conversation delv...
|
- Details
- Alicia Morgans is joined by Toni Choueiri in a discussion on the COSMIC-313 examining the role of triplet therapy with cabozantinib, nivolumab and ipilimumab as first-line treatment in patients with advanced renal cell carcinoma (RCC). The COSMIC-313 trial made strides at the 2022 ESMO meeting being a presidential symposium reporting the first phase 3 clinical trial in advanced RCC to use a contem...
|
- Details
- Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk non-met...
|
- Details
- Marc-Oliver Grimm joins Pedro Barata in a discussion on the final results of the TITAN-RCC trial, assessing a tailored approach to systemic therapy in patients with metastatic renal cell carcinoma (mRCC). The TITAN-RCC was designed many years ago, when nivolumab + ipilimumab (NIVO/IPI) was not approved yet as a first-line treatment. During this time the pivotal CheckMate 214 trial was still in pro...
|
- Details
- Laurence Albiges joins Pedro Barata highlighting the phase 2 KEYNOTE-B61 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). This is an area of unmet need and during the ESMO 2022 meeting, Dr. Albiges presented study data for the first time. KEYNOTE-B61 enroll patients with non-clear cell histology that have never been pre...
|
